Kasper W Ter Horst1, Pim W Gilijamse1, Mariette T Ackermans2, Maarten R Soeters1, Max Nieuwdorp3, Johannes A Romijn4, Mireille J Serlie5. 1. Department of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. 2. Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. 3. Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. 4. Department of Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. 5. Department of Endocrinology and Metabolism, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: m.j.serlie@amc.nl.
Abstract
AIM: Elevated basal endogenous glucose production (EGP), impaired suppression of EGP by insulin and reduced insulin-stimulated glucose disposal are cornerstones of the pathogenesis of hyperglycemia in patients with type 2 diabetes. We aimed to determine the contribution of these processes to impaired fasting glucose (IFG) levels in obese non-diabetic adults. METHODS: We included 131 obese non-diabetic adults with normal fasting glucose levels (NFG; fasting glucose <5.6mmol/L; 62 men, 25 women; mean±SEM age 49±1years; median (IQR) BMI 36 (34-41) kg/m(2)) or IFG (fasting glucose 5.6-6.9mmol/L; 35 men, 9 women; age 53±1years; BMI 36 (34-42) kg/m(2)) and studied basal EGP and hepatic, adipose tissue and peripheral insulin sensitivity by two-step euglycemic hyperinsulinemic clamp studies with [6,6-(2)H2]glucose infusion. RESULTS: Compared to equally obese adults with NFG, individuals with IFG did not differ in basal EGP (9.1±0.2 vs 9.8±0.3μmolkg(-1)min(-1), p=0.082), insulin-mediated suppression of circulating free fatty acid levels (75±1 vs 72±3%, p=0.240) and insulin-stimulated glucose disposal (26.6±1.0 vs 25.2±1.5μmolkg(-1)min(-1), p=0.441). Insulin-mediated suppression of EGP (68±2 vs 55±3%, p<0.001) was markedly reduced in obese subjects with IFG. CONCLUSIONS: Hepatic insulin resistance is a distinct metabolic feature of IFG in obesity. Insulin sensitivity of free fatty acid suppression and skeletal muscle does not differ between obese people with NFG and IFG. Hepatic insulin resistance may contribute to the onset of prediabetes in obese adults.
AIM: Elevated basal endogenous glucose production (EGP), impaired suppression of EGP by insulin and reduced insulin-stimulated glucose disposal are cornerstones of the pathogenesis of hyperglycemia in patients with type 2 diabetes. We aimed to determine the contribution of these processes to impaired fasting glucose (IFG) levels in obese non-diabetic adults. METHODS: We included 131 obese non-diabetic adults with normal fasting glucose levels (NFG; fasting glucose <5.6mmol/L; 62 men, 25 women; mean±SEM age 49±1years; median (IQR) BMI 36 (34-41) kg/m(2)) or IFG (fasting glucose 5.6-6.9mmol/L; 35 men, 9 women; age 53±1years; BMI 36 (34-42) kg/m(2)) and studied basal EGP and hepatic, adipose tissue and peripheral insulin sensitivity by two-step euglycemic hyperinsulinemic clamp studies with [6,6-(2)H2]glucose infusion. RESULTS: Compared to equally obese adults with NFG, individuals with IFG did not differ in basal EGP (9.1±0.2 vs 9.8±0.3μmolkg(-1)min(-1), p=0.082), insulin-mediated suppression of circulating free fatty acid levels (75±1 vs 72±3%, p=0.240) and insulin-stimulated glucose disposal (26.6±1.0 vs 25.2±1.5μmolkg(-1)min(-1), p=0.441). Insulin-mediated suppression of EGP (68±2 vs 55±3%, p<0.001) was markedly reduced in obese subjects with IFG. CONCLUSIONS:Hepatic insulin resistance is a distinct metabolic feature of IFG in obesity. Insulin sensitivity of free fatty acid suppression and skeletal muscle does not differ between obesepeople with NFG and IFG. Hepatic insulin resistance may contribute to the onset of prediabetes in obese adults.
Authors: Mariam Alatrach; Christina Agyin; John Adams; Ralph A DeFronzo; Muhammad A Abdul-Ghani Journal: Diabetologia Date: 2017-03-22 Impact factor: 10.122
Authors: Theresia Sarabhai; Sabine Kahl; Julia Szendroedi; Daniel F Markgraf; Oana-Patricia Zaharia; Cristina Barosa; Christian Herder; Frithjof Wickrath; Pavel Bobrov; Jong-Hee Hwang; John Griffith Jones; Michael Roden Journal: JCI Insight Date: 2020-05-21
Authors: K W Ter Horst; K A van Galen; P W Gilijamse; A V Hartstra; P F de Groot; F M van der Valk; M T Ackermans; M Nieuwdorp; J A Romijn; M J Serlie Journal: Int J Obes (Lond) Date: 2017-05-03 Impact factor: 5.095
Authors: Mariam Alatrach; Christina Agyin; Rucha Mehta; John Adams; Ralph A DeFronzo; Muhammad Abdul-Ghani Journal: J Clin Endocrinol Metab Date: 2019-01-01 Impact factor: 5.958
Authors: Kasper W Ter Horst; Daniel F Vatner; Dongyan Zhang; Gary W Cline; Mariette T Ackermans; Aart J Nederveen; Joanne Verheij; Ahmet Demirkiran; Bart A van Wagensveld; Geesje M Dallinga-Thie; Max Nieuwdorp; Johannes A Romijn; Gerald I Shulman; Mireille J Serlie Journal: Diabetes Care Date: 2020-12-08 Impact factor: 17.152
Authors: Miikka-Juhani Honka; Aino Latva-Rasku; Marco Bucci; Kirsi A Virtanen; Jarna C Hannukainen; Kari K Kalliokoski; Pirjo Nuutila Journal: Eur J Endocrinol Date: 2018-03-13 Impact factor: 6.664
Authors: Marti Boss; Hanne M M Rooijackers; Mijke Buitinga; Marcel J R Janssen; Anne I J Arens; Lioe-Fee de Geus-Oei; Liesbeth P Salm; Bastiaan E de Galan; Martin Gotthardt Journal: Eur J Clin Invest Date: 2019-04-29 Impact factor: 4.686